Status:
WITHDRAWN
MDX-060 in Patients With Relapsed or Refractory Classic Systemic or Primary Cutaneous Anaplastic Large Cell Lymphoma
Lead Sponsor:
Bristol-Myers Squibb
Conditions:
Lymphoma, Large-Cell
Eligibility:
All Genders
12+ years
Phase:
PHASE2
Brief Summary
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL who have relapsed or refractory disease. There will be 3 phases of this study: Induction, Maintenance, and F...
Detailed Description
This study is an open-label, fixed-dose, multicenter study of MDX-060 in patients with ALCL who have relapsed or refractory disease. There will be 3 phases of this study: Induction, Maintenance, and F...
Eligibility Criteria
Inclusion
- signed informed consent
- confirmed diagnosis of ALCL
- patient with csALCL must be confirmed CD30+
- patients with csALCL must have failed or relapsed following second line (i.e. salvage) chemotherapy or relapsed or failed following autologous stem cell transplant.
- patients with pcALCL must have progressed after treatment with local radiation therapy or surgical excision or failed systemic therapy with a single agent or multi-agent regimen.
- patients with pcALCL must be confirmed CD30+
- ECOG performance of 0 to 2
- at least 12 years of age
- life expectancy 12 weeks or greater
- must meet screening laboratory values
- women must be post-menopausal for at least 1 year; surgically incapable of bearing children; or utilizing a reliable form of contraception. All women must have a negative pregnancy test.
- men must agree to the use of male contraception for the duration of the study
- patients on corticosteroids must be tapered off the medication 2 weeks prior to the first MDX-060 administration and remain off corticosteroids until day 365.
Exclusion
- previous treatment with any anti-CD30 antibody
- history of allogenic transplantation
- any tumor lesion 10 cm or greater in diameter
- any other malignancy, excluding basal or squamous cell carcinoma of the skin, or cervical carcinoma in situ. Any cancer from which the patient has been disease free for at least 5 years is permissible.
- any significant acter or chronic infection.
- prior known serum positivity for HIV, hepatitis B or C as determined at screening.
- treatment with an investigational agent within 30 days or 5 half-lives (whichever is longer) of study screening.
- apparent active or latent tuberculosis infection (TB).
- patients who are pregnant or nursing
- any underlying medical condition which, in the investigator's opinion, will make the administration of MDX-060 hazardous or obscure the interpretation of adverse events.
- concomitant chemotherapy, corticosteroids, investigational agents, other anti-ALCL biologics, or radiation therapy
- patients with mycosis fungoides, or
- patients with recurrent, self-healing papulonodular eruptions only or any other lymphoma other than ALCL.
Key Trial Info
Start Date :
February 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
Estimated Enrollment :
45 Patients enrolled
Trial Details
Trial ID
NCT00298467
Start Date
February 1 2006
Last Update
April 26 2010
Active Locations (8)
Enter a location and click search to find clinical trials sorted by distance.
1
City of Hope, National Medical Center
Duarte, California, United States, 91010
2
California Oncology of the Central Valley
Fresno, California, United States, 93710
3
Moores UCSD Cancer Center
La Jolla, California, United States, 92093
4
Mayo Clinic
Rochester, Minnesota, United States, 55905